AstraZeneca

AstraZeneca Equity

The The Equity of AstraZeneca (AZN.L) as of Nov 5, 2026 is 48.67 B USD. In the previous year, The Equity was 40.79 B USD — a change of 19.32% (higher).

Equity

48.67 BUSD

YoY

19.32%

Last updated:

In 2025, AstraZeneca's equity was 48.67 B USD, a 19.32% increase from the 40.79 B USD equity in the previous year.

The AstraZeneca Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
12.47 B USD
Jan 1, 2019
13.13 B USD
Jan 1, 2020
15.62 B USD
Jan 1, 2021
39.27 B USD
Jan 1, 2022
37.04 B USD
Jan 1, 2023
39.14 B USD
Jan 1, 2024
40.79 B USD
Jan 1, 2025
48.67 B USD
The AstraZeneca Equity history
YEAREquityYoY
48.67 BUSD+19.32%
40.79 BUSD+4.20%
39.14 BUSD+5.69%
37.04 BUSD-5.68%
39.27 BUSD+151.36%
15.62 BUSD+19.01%
13.13 BUSD+5.29%
12.47 BUSD-16.66%
14.96 BUSD+0.71%
14.85 BUSD-19.66%
18.49 BUSD-5.79%
19.63 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AstraZeneca Stock analysis

What does AstraZeneca do? AstraZeneca PLC is a globally operating pharmaceutical company with its headquarters in England. The company was founded in 1999 through the merger of the Swedish company Astra AB and the British Zeneca Group PLC. Today, AstraZeneca employs more than 70,000 people and operates in over 100 countries. AstraZeneca specializes in the development, manufacturing, and marketing of pharmaceutical products. The company focuses primarily on oncology, cardiovascular and metabolic diseases, respiratory diseases, and autoimmune diseases. AstraZeneca is divided into various business segments. The oncology segment is a major focus of the company. Here, medications for various types of cancer are developed and manufactured. One particularly well-known product is the breast cancer medication Tamoxifen. In the cardiovascular and metabolic diseases segment, AstraZeneca offers various medications for heart and circulatory diseases as well as diabetes. One of the most well-known medications is Crestor, which is used to lower cholesterol levels. Another important area for AstraZeneca is respiratory diseases. Medications for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are developed and manufactured here. The medication Pulmicort is particularly well-known among asthma patients. Finally, AstraZeneca is also active in the field of autoimmune diseases. Medications against lupus erythematosus and rheumatoid arthritis are developed and manufactured here. AstraZeneca strives to improve healthcare worldwide through research and development of new medications. The company works closely with universities and research institutions and invests billions of dollars annually in research and development. AstraZeneca also pursues a sustainable business strategy and emphasizes acting environmentally and socially responsibly. The company is committed to reducing CO2 emissions and minimizing waste production. Over the years, AstraZeneca has received numerous awards and prizes, including the Sunday Times Innovation Award of the Decade, the Fierce Biotech Award for the medication Tagrisso, and the Prix Galien USA Award for Crestor. AstraZeneca aims to develop innovative medications that improve the lives of patients and advance healthcare worldwide. The company believes in a sustainable business strategy and actively promotes environmental and social responsibility. AstraZeneca will remain an important player in the global pharmaceutical industry in the future. AstraZeneca is one of the most popular companies on Eulerpool.

Equity Details

Analyzing AstraZeneca's Equity

AstraZeneca's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding AstraZeneca's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating AstraZeneca's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

AstraZeneca's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in AstraZeneca’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about AstraZeneca stock

The Equity of AstraZeneca is 48.67 B USD in 2025.

The Equity of AstraZeneca changed from 40.79 B USD to 48.67 B USD, representing a 19.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity AstraZeneca since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's AstraZeneca historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — AstraZeneca

All Key Metrics — AstraZeneca